
Rockwell Medical RMTI
$ 1.22
27.44%
Quarterly report 2025-Q3
added 11-12-2025
Rockwell Medical Book Value 2011-2026 | RMTI
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Rockwell Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.3 M | 14.1 M | 2.54 M | 34.2 M | 20.3 M | 27.3 M | 32.9 M | 53 M | 62.3 M | 68.7 M | 596 K | -9.96 M | 18.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 68.7 M | -9.96 M | 26.6 M |
Quarterly Book Value Rockwell Medical
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37 M | 30.4 M | 32.6 M | 29.1 M | 23.5 M | 20.6 M | 21.3 M | 21.5 M | 9.53 M | 12.5 M | 14.1 M | 16.1 M | 20.1 M | -4.81 M | 2.54 M | 11.1 M | 18.2 M | 26.2 M | 34.2 M | 34.2 M | 34.2 M | 34.2 M | 20.3 M | 20.3 M | 20.3 M | 20.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 32.9 M | 32.9 M | 32.9 M | 32.9 M | 83.2 M | 83.2 M | 83.2 M | 83.2 M | 87.8 M | 87.8 M | 87.8 M | 87.8 M | 98 M | 98 M | 98 M | 98 M | 36.4 M | 36.4 M | 36.4 M | 36.4 M | 17 M | 17 M | 17 M | 17 M | 31.9 M | 31.9 M | 31.9 M | 31.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 98 M | -4.81 M | 38.2 M |
Book Value of other stocks in the Drug manufacturers industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
8 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-651 K | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | ||
|
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | ||
|
Canopy Growth Corporation
CGC
|
487 M | $ 1.14 | -4.62 % | $ 123 M | ||
|
Cronos Group
CRON
|
1.71 B | $ 2.56 | 1.24 % | $ 1.35 B | ||
|
Cumberland Pharmaceuticals
CPIX
|
22.5 M | $ 4.74 | 1.94 % | $ 66.6 M | ||
|
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
314 M | - | 2.45 % | $ 38.1 M | ||
|
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | ||
|
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
649 M | $ 11.08 | 0.82 % | $ 567 M | ||
|
Athenex
ATNX
|
-24.2 M | - | -23.39 % | $ 1.76 M | ||
|
Evolus
EOLS
|
5.52 M | $ 5.05 | -2.88 % | $ 313 M | ||
|
Harrow Health
HROW
|
70.4 M | $ 47.49 | -0.86 % | $ 1.55 B | ||
|
China Pharma Holdings
CPHI
|
7.75 M | $ 1.25 | - | $ 21.8 M | ||
|
Jupiter Wellness
JUPW
|
-2.17 M | - | - | $ 33.6 M | ||
|
OrganiGram Holdings
OGI
|
306 M | $ 1.62 | 0.62 % | $ 402 M | ||
|
Bausch Health Companies
BHC
|
-82 M | $ 6.75 | -3.3 % | $ 2.46 B | ||
|
Neoleukin Therapeutics
NLTX
|
186 M | - | - | $ 193 M | ||
|
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | ||
|
Sundial Growers
SNDL
|
1.13 B | $ 1.58 | -2.17 % | $ 3.37 M | ||
|
Organogenesis Holdings
ORGO
|
385 M | $ 3.64 | -3.96 % | $ 479 M | ||
|
Pacira BioSciences
PCRX
|
778 M | $ 19.43 | 1.38 % | $ 899 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | $ 21.51 | 0.14 % | $ 2.05 B | ||
|
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
4.32 B | $ 15.06 | 0.2 % | $ 2.07 B | ||
|
Aurora Cannabis
ACB
|
609 M | $ 4.14 | -2.13 % | $ 86.3 M | ||
|
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | ||
|
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | ||
|
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 3.33 | 1.06 % | $ 4.13 M | ||
|
Relmada Therapeutics
RLMD
|
85.4 M | $ 3.93 | 5.01 % | $ 118 M | ||
|
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
138 M | $ 12.04 | 4.88 % | $ 855 M | ||
|
Tilray
TLRY
|
3.33 B | $ 8.74 | -7.62 % | $ 5.4 B | ||
|
PLx Pharma
PLXP
|
51.7 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
137 M | $ 5.59 | 2.19 % | $ 228 M | ||
|
SCYNEXIS
SCYX
|
73 M | $ 0.65 | -0.68 % | $ 31.1 M | ||
|
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | ||
|
Veru
VERU
|
32.3 M | $ 2.53 | -5.95 % | $ 341 M | ||
|
TherapeuticsMD
TXMD
|
29.3 M | $ 2.55 | 14.39 % | $ 26.6 M | ||
|
Viatris
VTRS
|
21.1 B | $ 12.66 | -1.59 % | $ 15.3 B | ||
|
Zomedica Corp.
ZOM
|
240 M | - | -0.21 % | $ 98 M | ||
|
cbdMD
YCBD
|
1.96 M | $ 0.83 | -9.94 % | $ 3.58 M |